Odyssey Therapeutics, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
This is Odyssey Therapeutics' Q3 2026 quarterly report (period ending 2026-09-30), filed 2026-11-04. The filing document itself contains no specific transaction details, financial results, counterparty names, dollar amounts, or material business developments in the header/metadata provided. Full financial statements and MD&A would be in the complete 10-Q document (3.9 MB iXBRL file), which is not reproduced in this excerpt.
Why this rating
Routine periodic SEC disclosure with no disclosed material event, transaction, or financial change. Standard quarterly reporting.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.